Compare AbCellera Biologics Inc (ABCL) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Deutsche Bank AG — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while Deutsche Bank AG trades at $35.09 (market cap $70.38B). The key difference: Deutsche Bank AG is far larger — about 29.9× AbCellera Biologics Inc's market cap, and Deutsche Bank AG pays a 3.17% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DB | |
|---|---|---|
Market Cap | $2.35B | $70.38B |
Sector | Health | Financials |
52-Week High | $8.12 | $40.33 |
52-Week Low | $2.78 | $28.37 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Deutsche Bank (DB) trades at $36.64, up 2.18% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamental momentum with three consecutive quarterly EPS beats and a net income margin of 21.98% for 2025. Recent strategic moves include selling its India retail unit to Kotak to sharpen focus on higher-growth businesses, while maintaining a dividend payout of $1.00 for H1-26.
The outlook remains positive with revenue growth to $32.2B projected for 2026 and a profit margin of 21.97%. Investment opportunities include attractive valuation with P/E of 10.29 and P/B of 0.8, but risks involve negative operating cash flow of -$28.58B in 2024 and competitive pressures from JPMorgan's expansion in Germany.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
